As of 2024-12-14, the EV/EBITDA ratio of Lexicon Pharmaceuticals Inc (LXRX) is -1.80. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. LXRX's latest enterprise value is 358.26 mil USD. LXRX's TTM EBITDA according to its financial statements is -198.69 mil USD. Dividing these 2 quantities gives us the above LXRX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 14.2x - 17.1x | 15.9x |
| Forward P/E multiples | 15.1x - 23.0x | 15.5x |
| Fair Price | (8.48) - (9.58) | (8.81) |
| Upside | -1146.6% - -1282.2% | -1187.3% |
| Date | EV/EBITDA |
| 2024-12-12 | -1.76 |
| 2024-12-11 | -1.95 |
| 2024-12-10 | -1.66 |
| 2024-12-09 | -1.67 |
| 2024-12-06 | -1.61 |
| 2024-12-05 | -1.51 |
| 2024-12-04 | -1.58 |
| 2024-12-03 | -1.63 |
| 2024-12-02 | -1.79 |
| 2024-11-29 | -1.79 |
| 2024-11-27 | -1.79 |
| 2024-11-26 | -1.82 |
| 2024-11-25 | -1.81 |
| 2024-11-22 | -1.90 |
| 2024-11-21 | -1.73 |
| 2024-11-20 | -1.80 |
| 2024-11-19 | -1.93 |
| 2024-11-18 | -1.98 |
| 2024-11-15 | -2.10 |
| 2024-11-14 | -2.26 |
| 2024-11-13 | -2.31 |
| 2024-11-12 | -2.49 |
| 2024-11-11 | -2.64 |
| 2024-11-08 | -2.64 |
| 2024-11-07 | -2.69 |
| 2024-11-06 | -2.53 |
| 2024-11-05 | -2.49 |
| 2024-11-04 | -2.52 |
| 2024-11-01 | -2.55 |
| 2024-10-30 | -3.88 |
| 2024-10-29 | -4.02 |
| 2024-10-28 | -3.71 |
| 2024-10-25 | -3.60 |
| 2024-10-24 | -3.68 |
| 2024-10-23 | -3.71 |
| 2024-10-22 | -3.86 |
| 2024-10-21 | -3.88 |
| 2024-10-18 | -4.11 |
| 2024-10-17 | -3.99 |
| 2024-10-16 | -3.80 |
| 2024-10-15 | -3.59 |
| 2024-10-14 | -3.59 |
| 2024-10-11 | -3.49 |
| 2024-10-10 | -3.40 |
| 2024-10-09 | -3.29 |
| 2024-10-08 | -3.39 |
| 2024-10-07 | -3.39 |
| 2024-10-04 | -3.40 |
| 2024-10-03 | -3.26 |
| 2024-10-02 | -3.26 |